Gemcitabine (G) and irinotecan (CPT-11) as first-line therapy for carcinoma (ca) of unknown primary (CUP): An NCCTG phase II trial

被引：1
|
作者：
Holtan, S. G.
Foster, N. R.
Erlichman, C. E.
Aubry, M.
Ames, M. M.
Safgren, S.
Steen, P. D.
Morton, R. F.
Graham, D.
Goetz, M. P.
机构：
[1] Mayo Clin, Rochester, MN USA
[2] MeritCare Hosp CCOP, Fargo, ND USA
[3] Iowa Oncol Res Assoc CCOP, Pleasant, IA USA
[4] Carle Canc Ctr, Urbana, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.13525
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
13525
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Gemcitabine and Irinotecan as First-Line Therapy for Carcinoma of Unknown Primary: Results of a Multicenter Phase II Trial
    Holtan, Shernan G.
    Steen, Preston D.
    Foster, Nathan R.
    Erlichman, Charles
    Medeiros, Fabiola
    Ames, Matthew M.
    Safgren, Stephanie L.
    Graham, David L.
    Behrens, Robert J.
    Goetz, Matthew P.
    PLOS ONE, 2012, 7 (07):
  • [2] Phase II study of carboplatin (CBDCA) and irinotecan (CPT-11) for patients with cancer of unknown primary (CUP)
    Ando, M., Sr.
    Yonemori, K.
    Yunokawa, M.
    Nakano, E.
    Kouno, T.
    Shimizu, C.
    Katsumata, N.
    Tamura, K.
    Arioka, H.
    Fujiwara, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma
    Sanz-Altamira, PM
    O'Reilly, E
    Stuart, KE
    Raeburn, L
    Steger, C
    Kemeny, NE
    Saltz, LB
    ANNALS OF ONCOLOGY, 2001, 12 (04) : 501 - 504
  • [4] Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma
    Poon, D
    Chowbay, B
    Cheung, YB
    Leong, SS
    Tan, EH
    CANCER, 2005, 103 (03) : 576 - 581
  • [5] Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer
    Sugiyama, T
    Yakushiji, M
    Kamura, T
    Ikeda, M
    Umesaki, N
    Hasegawa, K
    Ishikawa, M
    Saji, F
    Hiura, M
    Takahashi, T
    Sato, S
    Ochiai, K
    Kikkawa, F
    Takeuchi, S
    Ohashi, Y
    Noda, K
    ONCOLOGY, 2002, 63 (01) : 16 - 22
  • [6] Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma (NPC).
    Poon, D
    Chowbay, B
    Leong, SS
    Cheung, YB
    Toh, CK
    Tay, MH
    Lim, WT
    Tan, EH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 507S - 507S
  • [7] Phase I/II trial of gemcitabine (Gem) plus irinotecan (CPT-11) for metastatic pancreatic cancer (MPC)
    Yamai, Takuo
    Ioka, Tatsuya
    Sueyoshi, Hironari
    Takada, Ryoji
    Fukutake, Nobuyasu
    Ashida, Reiko
    Katayama, Kazuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [8] Irinotecan (CPT-11) and cisplatin as first-line chemotherapy in advanced ovarian cancer.
    Sugiyama, T
    Noda, K
    Yakushiji, M
    Kamura, T
    ANNALS OF ONCOLOGY, 2000, 11 : 86 - 86
  • [9] Phase II trial and pharmacokinetic study of irinotecan (CPT-11) in patients with glioblastoma
    Boige, V
    Raymond, E
    Fabbro, M
    Plazza, J
    Vassal, G
    Risse, ML
    Rodier, JM
    Armand, JP
    ANNALS OF ONCOLOGY, 1998, 9 : 137 - 137
  • [10] A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
    Rothenberg, ML
    Cox, JV
    DeVore, RF
    Hainworth, JD
    Pazdur, R
    Rivkin, SE
    Macdonald, JS
    Geyer, CE
    Sandbach, J
    Wolf, SL
    Mohrland, JS
    Elfring, GL
    Miller, LL
    Von Hoff, DD
    CANCER, 1999, 85 (04) : 786 - 795
12345